New biosimilar for breast cancer under Real-World watch
NCT ID NCT07542496
First seen Apr 28, 2026 · Last updated May 25, 2026 · Updated 6 times
Summary
This study follows 1,000 people with HER2-positive breast cancer to see how a biosimilar version of pertuzumab is used in everyday care. It looks at treatment patterns, tumor response, and side effects in two groups: those getting the drug before surgery and those receiving it as first treatment for advanced cancer. The goal is to confirm the biosimilar works as well as the original drug in real-world settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CAC BLIDA, Algiers, Algeria 16000
RECRUITINGAlgiers, Algeria
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Béni Messous, Algiers, Algeria 16000
RECRUITINGAlgiers, Algeria
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.